The first phase of the roll-out of hybrid closed loop systems to NHS integrated care systems continues.
Following a successful pilot by NHS England, in December 2023 the National Institute for Health and Care Excellence recommended that HCL technology should be rolled-out in a phased implementation, over the next five years, to thousands of Type 1 diabetes patients including:
- Adults who have an HbA1c of 58 mmol/mol (7.5%) or higher, or have disabling hypoglycaemia, despite best possible management with at least one of the following:
- continuous subcutaneous insulin infusion
- real-time CGM
- intermittently scanned CGM
- Children and young people (under 18 years old)
- Women, trans men and non-binary people who are pregnant or planning to become pregnant.
All patients who are eligible are advised to continue to attend appointments as normal and discuss options with their diabetes team.
To find out more, CLICK HERE.
